secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K/A
Filed at:   2021-09-30T23:59:59+00:00
Accession:  0001193125-21-287569
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics corrects option grant details for new CFO Maestas
----------------------------------------------------------------------

- Nicholas Maestas appointed VP, Strategy & Finance and principal financial officer effective July 12, 2021.
- Annual base salary of $325,000 with target performance bonus of 30% of base salary.
- Option to purchase 23,225 shares at July 12 closing price; vesting: 25% after one year then monthly over 36 months.
- This amendment corrects a clerical error in the original 8-K regarding the option grant terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521287569/0001193125-21-287569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521287569/d238646d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-287569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer